In truth, it appears that TransMedics fueled its growth by engaging in an anti-competitive scheme, including providing kickbacks to medical providers. The company further boosted growth by engaging in ...

So, it was a healthy start to the year, M&A-wise, for one of the worst-performing sectors of the S&P 500® in 2024. The Health ...

QMines (ASX:QML) has reported a string of stunning high grade copper intercepts at its Develin Creek project near Rockhampton ...

LOS ANGELES, CA / ACCESS Newswire / February 6, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

Shares of TransMedics, Group Inc. (NASDAQ: TMDX) suffered a sharp decline over the past two trading days following the release of a ...

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...

Block & Leviton is investigating TransMedics Group, Inc. (Nasdaq: TMDX) for potential securities law violations. Investors who have lost money in their TransMedics ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases like ulcerative colitis. Read the pre-IPO report here.

TransMedics Group, Inc. TMDX recently issued a statement refuting the claims made in a report by short-seller Scorpion Capital on Jan. 10, 2025, stating them as inaccurate and misleading.